|
[1]
|
Robbins RJ. Pharmacology of bovine and human thyrotropin:an historical perspective[J]. Thyroid, 1999, 9(3):451-453. |
|
[2]
|
Robbins RJ, Tuttle RM, Sonenberg M, et al. Radio-iodine ablation of thyroid remnants after preparation with recombinant human thyrotropin[J]. Thyroid, 2001, 11(6):865-869. |
|
[3]
|
Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation[J]. J Nucl Med, 2002, 43(7):1482-1488. |
|
[4]
|
Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30mCi of 131I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal[J]. J Clin Endocrinol Metab, 2002, 87(6):4063-4068. |
|
[5]
|
Barbaro D, Boni G, Meucci G, et al. Radio-iodine treatment with 30mCi after recombinant human thyrotropin stimulation in thyroid cancer:Effectiveness for postsurgical remnant ablation and possible role of iodine content in L-thyroxine in the outcome of ablation[J]. J Clin Endocrinol Metab, 2003, 89(6):4110-4115. |
|
[6]
|
Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyrotropin before radio-iodine therapy in patients with advanced differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2000, 85(5):3640-3645. |
|
[7]
|
Lippi F, Capezzone M, Angelini F, et al. Radio-iodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine,using recombinant human TSH[J]. Eur J Endocrinol, 2001, 144(1):5-11. |
|
[8]
|
Berg G, Lindstedt G, Suurkula M, et al. Radio-iodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone[J]. J Endocrinol Inv, 2002, 25(1):44-52. |
|
[9]
|
de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer[J]. J Nucl Med, 2004, 45(9):1549-1554. |
|
[10]
|
Santini F, Bottici V, Elisei R, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2002, 87(6):4160-4165. |
|
[11]
|
Haugen BR. Management of the patient with progressive radioiodine non-responsive disease[J]. Semin Sur Oncol, 1999, 16(1):34-41. |
|
[12]
|
Huysmans DA, Nieuwlaat WA, Erdtsieck R J, et al. Administration of a single low dose of recombinant human thyrotrepin significantly enhances thyroid radio-iodide uptake in nontoxic nodular goiter[J].J Clin Endocrinol Metab, 2000, 85(5):3592-3596. |
|
[13]
|
Nieuwlaat WA, Huysmans DA, Van den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radio-iodine therapy in patients with nodular goiters[J]. J Clin Endocrinol Metab, 2003, 88(4):3121-3129. |
|
[14]
|
Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radio-iodine uptake and treatment of nontoxic and toxic multinodular goiters[J]. Endocr Pract, 2003, 9:204-209. |
|
[15]
|
Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres[J]. Clin Endocrinol (Oxf), 2004, 60(3):300-308. |
|
[16]
|
Nielsen VE, Bonnema SJ, Boel-Jorgensen H, et al. Recombinant human thyrotropin (rhTSH)markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter.. An evaluation by a randomized double-blinded trial[J]. J Clin Endocrinol Metab, 2004, 90(1):79-83. |
DownLoad: